Pharmacogenomic-Guided Antidepressant Drug Prescribing in Cancer Patients
NCT ID: NCT03674138
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
99 participants
INTERVENTIONAL
2018-09-12
2024-10-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DNA-guided choice of therapy
DNA-guided choice of antidepressant therapy
DNA-guided choice of therapy
Buccal swab for DNA genotyping to identify best antidepressant therapy
Clinical management
Clinical management
DNA-guided choice of therapy
Buccal swab for DNA genotyping to identify best antidepressant therapy
Clinical management
Clinical management to identify best antidepressant therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA-guided choice of therapy
Buccal swab for DNA genotyping to identify best antidepressant therapy
Clinical management
Clinical management to identify best antidepressant therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be 18 years of age or older
* Patients who rate depression or anxiety \> 5 based on a 10 point scale
* Patients expected to live greater than 6 months
* Serum bilirubin and creatinine \< 1.5x upper limit of normal
* AST and ALT \< 3 times upper limit of normal
* Willing and able to provide written informed consent
* Able to complete self-assessment questionnaires
Exclusion Criteria
* Antidepressant prescribing performed by a non-Moffitt psychiatrist after enrollment onto the clinical trial
* Known Pregnancy
* History of liver or allogenic stem cell transplant
* Patients with a known cognitive impairment (e.g., delirium, dementia, etc.) or psychological impairment (e.g., schizophrenia, bipolar disease, etc.) other than depressive and anxiety symptoms.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James K Hicks, PharmD, PhD
Role: PRINCIPAL_INVESTIGATOR
H. Lee Moffitt Cancer Center and Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCC-19578
Identifier Type: -
Identifier Source: org_study_id